Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Status:
Completed
Trial end date:
2019-06-12
Target enrollment:
Participant gender:
Summary
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing
properties. The primary target is the dopamine D3 receptor, a target implicated in the
generation of levodopa-induced dyskinesia, a side-effect frequently occurring with long-term
levodopa treatment in patients with Parkinson's disease. In experimental animals mesdopetam
potently reduced levodopa-induced involuntary movement without impairing the antiparkinsonian
effect of levodopa.
The primary purpose of the trial is to investigate whether mesdopetam given as adjunctive
treatment can reduce levodopa induced dyskinesia in patients with Parkinson's disease. The
trial will also help to establish the most optimal dosing of the compound.